《Medicalxpress,12月13日,Scientists develop an RNA-based breath test to detect COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: YUTING
  • 发布时间:2021-12-18
  • In a new study in The Journal of Molecular Diagnostics, investigators report on the design and testing of a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2. Its name is derived from the bubbling sound that occurs when the patient exhales into the device.

    The Bubbler not only reverse transcribes RNA from airborne virus particles into DNA to be tested via PCR but can also barcode that DNA, allowing samples to be linked directly to the patient they have come from and be used for sequencing. It can be used for simultaneous batches of pooled samples and provides additional information such as viral load and strain identity and eliminates the need for stabilizing a sample, potentially allowing the assay to be performed at home.

    "Involvement of the lower respiratory tract is often a precursor to severe COVID-19, so there is an argument for a more direct sampling focused on exhaled breath," explained lead investigator William G. Fairbrother, Ph.D., professor in the department of molecular biology, cell biology and biochemistry at Brown University in Providence, RI, U.S.

    Virus detection by the Bubbler is similar to a hospital-swab PCR test; however, it is a better measure of risk of contagion as it detects airborne viral particles. Swab tests can return a positive result for months after infection as they detect viral RNA fragments in cells that persist in previously infected cells. The Bubbler can also be adapted for environmental sampling in hospitals, transportation hubs, and closed environments like offices, ships, and planes, the investigators report.

    Seventy patients treated in the Emergency Department of Rhode Island Hospital between May 2020 and January 2021 were screened. The study tested samples from three points in the respiratory tract. Tongue scrapes from the mouth (saliva/tongue scrapes) and from 15 seconds of exhaled breath collected in the Bubbler were compared to those from a conventional nasopharyngeal swab PCR test. The Bubbler is a glass tube with a glass pipette through which patients can exhale. The tube is filled with a reverse transcription reaction mixture and cold mineral oil.

  • 原文来源:https://medicalxpress.com/news/2021-12-scientists-rna-based-covid-.html
相关报告
  • 《Medicalxpress,12月8日,Breakthrough COVID-19 saliva amplified antigen rapid test is as sensitive as PCR test》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2021-12-15
    • A potentially game-changing antigen rapid test (ART) technology to diagnose COVID-19 has been developed by scientists in Singapore. Using a proprietary on-kit amplification technique, a person's saliva can be self-administered or tested for the SARS-CoV-2 virus at the point-of-care with sensitivity higher than current ART tests and close to that of laboratory-based polymerase chain reaction (PCR) tests. Dubbed the Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), the technology produces results in minutes, without the need for additional equipment or specially-trained personnel. The invention was borne out of a research collaboration between Duke-NUS Medical School, Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS)—collectively member institutes of the SingHealth Duke-NUS Academic Medical Centre—and the National University of Singapore (NUS). With the impending availability of oral antiviral drugs against SARS-CoV-2, COVID-19 could potentially be diagnosed and treated in the primary care setting in the future. A test that can be done on-site will enable doctors to diagnose COVID-19 accurately and prescribe the drugs appropriately. Moreover, with its anticipated low cost and ease of use as compared to PCR tests, PASPORT could aid Singapore and countries around the world in making early diagnosis of COVID-19 to initiate appropriate case management. The research was published online on Monday, 6 December, 2021, in the journal Microchimica Acta as a feature article in their series, 'From Bench to Hand'. "Testing is an indispensable tool in the management of COVID-19 cases. Although PCR has been the gold standard, it requires trained personnel and laboratory infrastructure," said lead inventor Dr. Danny Jian Hang Tng, Medical Officer at the Department of Infectious Diseases, SGH, and an adjunct Research Fellow at Duke-NUS' Emerging Infectious Diseases (EID) Programme. Dr. Tng, who graduated from Duke-NUS in 2019, added, "A reliable and painless saliva antigen test that is affordable and convenient to perform would encourage more to be tested, and more frequent testing. This may enable us to manage COVID-19 more effectively not only at the point of care, but also in settings such as airports, conventions and even at home."
  • 《Medicalxpress,12月13日,Researchers develop a molecule that blocks SARS-CoV-2 infection》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2021-12-18
    • A research team at Aarhus University has developed a new molecule that attaches to the surface of SARS-CoV-2 virus particles. This attachment prevents the virus from entering human cells and spreading the infection. The newly developed molecule belongs to a class of compounds known as RNA aptamers and it is based on the same type of building blocks that are used for mRNA vaccines. This makes them much cheaper and easier to manufacture than the antibodies that are currently used to treat COVID-19 and to detect viral infection using rapid antigen tests. An aptamer is a piece of DNA or RNA that folds into a 3D structure that can recognize a specific target molecule of interest. By attaching itself to the virus surface, the RNA aptamer prevents the Spike protein from serving as a key that allows the virus to enter a cell. Hence, the RNA aptamer is not a new type of vaccine but a compound that can potentially stop the virus from spreading in the body once someone is exposed to the virus. The efficient binding to SARS-CoV-2 virus also means that the aptamer can be used to test for COVID-19 infection. "We have started testing the new aptamer in rapid tests and we expect to be able to detect very low concentrations of the virus" says Professor Jørgen Kjems from Aarhus University who is the main author of the article which has just been published in the journal PNAS. Studies in cell culture show that the aptamer works against the previous variants of coronavirus that the researchers had the opportunity to test. "Since we submitted the article for peer review, we have continued our studies and been able to show that it also recognizes the delta variant. Now we are waiting for samples of the newly identified variant, omicron, so we can test whether the aptamer also recognizes that," says Jørgen Kjems.